This experiment investigates the role of metal ion dysregulation (copper, zinc, iron) in amyloid aggregation and neurotoxicity in Alzheimer's disease. Metal ion homeostasis is disrupted in AD brains, and metal-ion interactions with Aβ may accelerate plaque formation while also generating reactive oxygen species.
AD Gap #16: Role of metal ion dysregulation in amyloid aggregation
What is the relationship between metal ion dysregulation and amyloid aggregation, and can metal chelation therapies slow disease progression?
Copper, zinc, and iron dysregulation accelerates Aβ aggregation through direct metal-Aβ interactions and generates oxidative stress. Restoring metal homeostasis through chelation or ion channel modulation will reduce amyloid pathology and neurodegeneration.
Phase 1: Metal-Aβ Interaction Mapping
Phase 2: Cellular Metal Homeostasis
Phase 3: In Vivo Metal Modulation
| Factor | Rating | Notes |
|---|---|---|
| Technical feasibility | 8/10 | Well-established assays; metal quantification requires specialized equipment |
| Cost efficiency | 6/10 | ICP-MS and chelator synthesis add cost |
| Timeline | 12 months | In vitro (3 mo) + cellular (6 mo) + in vivo validation (6 mo) |
| Cross-disease value | 7/10 | Similar mechanisms in PD (iron) and ALS (copper) |
| Component | Cost (USD) |
|---|---|
| Personnel (2 FTE × 12 mo) | $240,000 |
| Metal assays and ICP-MS | $80,000 |
| iPSC differentiation | $60,000 |
| Animal work (100 mice) | $40,000 |
| Chelator compounds | $20,000 |
| Total | $440,000 |
Total Score: 65 (Rank 78)
| Dimension | Score |
|---|---|
| Mechanistic Impact | 7 |
| Cure Proximity | 5 |
| Feasibility | 7 |
| Cost Efficiency | 6 |
| Timeline | 7 |
| Cross-Disease Value | 7 |
| Biomarker Enablement | 5 |
| Combinability | 6 |
| De-risking Value | 5 |
| Novelty | 6 |